KaliVir to Present at 2025 AACR Annual Meeting
KaliVir to Present at 2025 AACR Annual Meeting KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company specializing in the development of advanced oncolytic immunotherapies, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting. The event,…
Bayer Unveils New Heart Failure & Kidney Disease Research at ACC.25
Bayer Unveils New Heart Failure & Kidney Disease Research at ACC.25 Bayer has announced the presentation of 13 new data analyses from its comprehensive KERENDIA® (finerenone) clinical trial program at the American College of Cardiology (ACC) 74th Annual Scientific Session…
SOLVE FSHD Partners with Transcripta Bio to Accelerate Drug Discovery for FSHD
SOLVE FSHD Partners with Transcripta Bio to Accelerate Drug Discovery for FSHD SOLVE FSHD, a venture philanthropy organization committed to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), has announced a strategic collaboration with Transcripta Bio, an innovative AI-driven drug discovery…
WHO Foundation and L’Oréal Partner to Advance Global Skin Health
WHO Foundation and L’Oréal Partner to Advance Global Skin Health The WHO Foundation and L’Oréal Group, through its Dermatological Beauty division, have announced a landmark four-year partnership aimed at improving global access to skin health treatments. This initiative is particularly…
Vicarious Surgical Announces Leadership Transition for President
Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company dedicated to advancing the field of minimally invasive surgery, has announced a key leadership transition. Effective April 25, 2025, Randy Clark, the current…
Ant Group Announces Major AI Upgrades for Healthcare Solutions
Ant Group has announced significant upgrades to its full-suite AI solutions for the healthcare sector, reinforcing its commitment to supporting hospitals, doctors, and users through cutting-edge artificial intelligence. These advancements aim to enhance operational efficiency, improve patient care, and offer…
Omnicell Appoints Perry A. Genova, PhD, as Chief Technology Officer
Omnicell Appoints Perry A. Genova, PhD, as Chief Technology Officer Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming pharmacy and nursing care delivery, has announced the appointment of Perry A. Genova, PhD, as Senior Vice President…
Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer
Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer Byondis BV, an independent biopharmaceutical company dedicated to developing innovative, targeted medicines for cancer patients, has announced the appointment of Christoph Korpus, PhD, MBA, as its new Chief Business Officer…
Amplar Health and Australian Government Collaborate to Transform Aged Care with Virtual Nursing
Amplar Health and Australian Government Collaborate to Transform Aged Care with Virtual Nursing Amplar Health has announced a groundbreaking partnership with the Australian Government to introduce an innovative virtual nursing model aimed at supporting the aged care sector. This collaboration…
People-Powered, Tech-Enabled Pharmacy Experience
People-Powered, Tech-Enabled Pharmacy Experience A Tech-Enabled, People-Powered Pharmacy Experience Digital First, Not Digital Only In today’s rapidly evolving healthcare landscape, technology plays a crucial role in enhancing pharmacy care. Digital tools provide accessibility, personalization, and convenience, improving the overall experience…
Omeros Updates Zaltenibart Phase 3 PNH Trial
Omeros Updates Zaltenibart Phase 3 PNH Trial Omeros Corporation (Nasdaq: OMER) has announced significant progress in its Phase 3 clinical trial program for zaltenibart (OMS906), an investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway…
VantAI Unveils Neo-1: AI Model for Molecular Interaction Design
VantAI Unveils Neo-1: AI Model for Molecular Interaction Design VantAI has unveiled Neo-1, the world’s most advanced atomistic foundation model, marking a significant milestone in molecular design and drug discovery. Announced at NVIDIA GTC 2025, Neo-1 is the first AI…